Brand Names:
Fungilin, Fungizone, Abelcet, AmBisome, Fungisome, Amphocil, Amphotec


Drug Type: Antifungal

Amphotericin B (Fungizone)


Amphotericin B (Fungizone) is one of the newer types of antifungal drugs. It is used most commonly to treat systemic fungal infections caused by Aspergillus species. However, it is effective against a wide range of fungi, including: Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum, Rhodotorula, Blastomyces dermatitidis, Mucor mucedo, and Sporothrix schenckii. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible.

Amphotericin B acts by binding to sterols (ergosterol) in the cell membrane of susceptible fungi. This creates a transmembrane channel, and the resultant change in membrane permeability allowing leakage of intracellular components. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of amphotericin B and the azoles.

Drug Form: Amphotericin B is available as an injectable solution (5 mg/ml) for slow (over a period of several hours) IV administration, in sinus flushes, intratracheally, or nebulized in conjunction with another antifungal drug. There is also a lotion or cream (3%) available that is often used for fungal dermatitis or oral candidiasis that is resistant to nystatin. If Amphotericin B is applied topically, it can be very irritating and so needs to be diluted in water.

Recommended dosage: If given by mouth, 100 mg/kg body weight. If given via IT, 1 mg/kg body weight. If given, IV, 1.5 mg/kg body weight.

Caution
If administered rapidly or if overdosed, can result in heart arrhythmias and cardio-respiratory arrest. Since the drug is eliminated by the kidneys, it has a high risk of causing kidney damage (nephrotoxicity) and thus should only be used for a short duration.
  • Kidney toxicity
  • Bone marrow damage
  • Depression
  • Irritation at the injection site
  • Acebutolol:The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acebutolol.
  • Amikacin: Amphotericin B may increase the nephrotoxic activities of Amikacin.
  • Apramycin: Amphotericin B may increase the nephrotoxic activities of Apramycin.
  • Betamethasone:Betamethasone may increase the hypokalemic activities of Amphotericin B
  • Chlorothiazide: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorothiazide.
  • Chlorpromazine: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorpromazine.
  • Clomipramine: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Clomipramine
  • Halothane: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.
  • Gentamicin: Amphotericin B may increase the nephrotoxic activities of Gentamicin.
  • Furosemide: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Furosemide.
  • Dexamethasone:Dexamethasone may increase the hypokalemic activities of Amphotericin B.
  • Cyclosporine: Amphotericin B may increase the nephrotoxic activities of Cyclosporine.
  • Clotrimazole:The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Clotrimazole
  • Nystatin:The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Nystatin.
  • Monensin:The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Monensin.
  • Miconazole:The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole.
  • Methylprednisolone: Methylprednisolone may increase the hypokalemic activities of Amphotericin B.
  • Magnesium Sulfate:The risk or severity of adverse effects can be increased when Amphotericin B is combined with Magnesium Sulfate.
  • Ketoconazole: The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ketoconazole.
  • Itraconazole:The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Itraconazole.
  • Isoflurane: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isoflurane.
  • Streptomycin:Amphotericin B may increase the nephrotoxic activities of Streptomycin.
  • Prednisone:Prednisone may increase the hypokalemic activities of Amphotericin B.